This extraordinary March and April – marked by rising numbers of Covid-19 cases and fatalities, suffering for patients and families, courageous efforts by clinicians, restricted social interaction, business closings, massive unemployment – has battered our healthcare system and economy. Here are a few early thoughts on how the evolving pandemic has changed the outlook for health policy after the November elections.
A bill to encourage the manufacture of active pharmaceutical ingredients in America was introduced in the U.S. Senate by Senators Marsha Blackburn (R-TN) and Bob Menendez (R-NJ).
The U.S. House of Representatives overwhelmingly approved an $8.3 billion bill to combat the spread of the new coronavirus and develop vaccines for the highly contagious disease, sending it to the Senate for final passage.
What will top the agenda of new U.S. FDA Commissioner Dr. Stephen Hahn?
The U.S. Senate confirmed Stephen Hahn as commissioner of the U.S. Food and Drug Administration in a 72-18 vote.
Main pharmaceutical industry lobbying group PhRMA and some drugmakers met with President Donald Trump to voice opposition to a bipartisan U.S. Senate bill that aims to lower prescription drug prices.
Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.
U.S. Senator Bernie Sanders unveiled the latest version of his ambitious “Medicare-for-All” plan, moving the healthcare debate among Democratic presidential contenders to center stage in the 2020 race.
U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines.
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.